Phaseline

Companies › MeiraGTx Ocular UK

MeiraGTx Ocular UK: clinical trials, targets and expected readouts

1 active drug program in 3 registered trials: 2 Phase 3, 1 Phase 2; Ophthalmology; next expected readout Jun 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
AAV5-hRKp.RPGR (botaretigene sparoparvovec, JNJ-74765340)
AAV5-mediated RPGR gene replacement
RPGRPhase 3Retinitis Pigmentosa; X-Linked Retinitis PigmentosaJun 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05926583AAV5-hRKp.RPGR (botaretigene sparoparvovec, JNJ-74765340)Phase 3Retinitis PigmentosaOphthalmologyJun 2027
NCT04794101AAV5-hRKp.RPGR (botaretigene sparoparvovec, JNJ-74765340)Phase 3X-Linked Retinitis PigmentosaOphthalmologySep 2029
NCT06646289AAV5-hRKp.RPGR (botaretigene sparoparvovec, JNJ-74765340)Phase 2X-Linked Retinitis PigmentosaOphthalmologyOct 2030

Targets

RPGR (1)

Companies with the same targets

Beacon Therapeutics 4D Molecular Therapeutics

Companies built like this

Beacon Therapeutics Tecnoquimicas Neurotech Pharmaceuticals Innostellar Biotherapeutics jCyte

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.